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As Shrivastava and Akowuah note, in our observational
study [1] we only recorded clodidogrel use within three
days prior to surgery indiscriminately if it was stopped 1,
2 or 3 days prior to surgery. However, onset of action can
be expected within hours (especially if a loading dose is
administered) and once established in therapy effects are
present for the lifespan of platelets. We therefore
appreciate the point if the mean time clopidogrel has
been stopped before surgery in the no clopidogrel group
was less than 7 days. Although this was not recorded for
study purpose (which is a limitation) clinical practice
allows to suggest that the majority of patients in the no
clopidogrel group have had no clopidogrel at all. In both
groups a comparable number of patients were on aspirin
(37.3% in the clopidogrel group vs. 41.5% in the no
clopidogrel group, PZns).
A recent meta-analysis of randomized clinical trials [2]
points out clearly, that concerns about perioperative
myocardial infarction (early graft closure) linked to aproti-
nin use are limited in evidence. This is in accordance to our
clinical experience. It has been recognized early that
aprotinin is also efficient for the reduction of blood loss
after CPB in a low-dose protocol [3]. We use it routinely in
the pump-prime dose (two million KIU) also in patients who
are not at an increased risk of bleeding supplemented by the
high dose protocol in patients are at risk.
As a next point Shrivastava and Akowuah presume a
possible bias due to different practice among the surgeons in
our unit. However, this can be ruled out by the fact that in
the respect of interest (stopping of clopidogrel before
surgery) our surgical group is very homogenous. Additionally,
the continental system of a surgical unit in a university
hospital differs from the consultant-system practiced in UK.
Finally we agree that further clinical trials are
welcomed in this field, especially including specificmeasurements of platelet function. In addition, factors
reducing perioperative bleeding complications (e.g. apro-
tinin and other antifibrinolytics) have to be evaluated for
patients operated under ongoing clopidogrel therapy.References
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D’Ancona et al. present important information on
coronary graft flow and optimal pacing techniques [1].
Optimal cardiovascular haemodynamics in the marginal
postoperative patient may enhance graft patency. This has
previously been shown in patients who require intra-aortic
balloon pump support [2].
A number of important points, however, need
clarification.
First, no mention of pre or postoperative intra-ventri-
cular conduction defects are mentioned. Patients with left
bundle branch block are significantly better cardiovascularly
after the specific pacing of the lateral aspect of the left
ventricle [3]. This has been shown in the cardiac resynchro-
nisation trials [4,5]. However D’Ancona et al. just mention
‘two ventricular pacing wires were placed in each patient’,
making no mention of the anatomical placement of the
electrodes.
Second, recommending an optimal A-V delay of 175 ms
is potentially non safe practice. Personnel experience of
altering A-V delay in A-V sequential paced patients, while
monitoring cardiac indices via Swan-Ganz catheter read-
ings shows that inter patient variability in optimal A-V
pacing delay is quite high. This fact is demonstrated by
their figure 1, which shows as the A-V delay is increased
from 100 to 175 ms, at least six of the ten patients had
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reported in the literature [3].References
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We have read with interest Dr Poullis letter and we
thank him for his timely comments. We are well aware
that, as specified by Dr Poullis, and demonstrated in
previous literature, optimal cardiovascular hemodynamics
in the marginal postoperative patient may enhance graft
patency or better improve myocardial perfusion. In reality
our study, differently from any other published in the
literature, including the resynchronization trials mentioned
by Dr Poullis, did not focus on the mere hemodynamic
parameter changes resulting from different pacing mod-
alities but did center on the immediate changes in
intraoperative coronary graft flows as measured by transit
time technique and as resulting from different pacing
techniques.
Ventricular pacing wires were routinely placed in the
right ventricle and right atrium and graft flows were
measured during DDD and VVI pacing and at different A-V
delays. Patients with preoperative atrio-ventricular or
intraventricular conduction anomalies were specifically
excluded from the study.
Although we do believe that DDD pacing can signifi-
cantly improve coronary grafts flow when compared to
VVI pacing, we do agree that it is difficult to indicate the
best A-V delay. The inter patient high variability in
optimal A-V pacing delay is not a secret and can be easily
deducted in the second part of our study where statistical
significance was not achieved. In this regard we are
extending our analysis to a larger group of patients with
the aim to better define a specific range of A-V delays
that may significantly allow for optimal flows in newly
constructed coronary grafts.
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